Beam Therapeutics (BEAM) Competitors $18.48 +0.84 (+4.76%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$16.98 -1.50 (-8.09%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM vs. ROIV, LNTH, BBIO, RVMD, LEGN, TGTX, SRPT, AXSM, BPMC, and TLXShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Roivant Sciences (ROIV), Lantheus (LNTH), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), Legend Biotech (LEGN), TG Therapeutics (TGTX), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Beam Therapeutics vs. Roivant Sciences Lantheus BridgeBio Pharma Revolution Medicines Legend Biotech TG Therapeutics Sarepta Therapeutics Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Roivant Sciences (NASDAQ:ROIV) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking. Does the MarketBeat Community prefer ROIV or BEAM? Beam Therapeutics received 11 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.26% of users gave Roivant Sciences an outperform vote while only 58.56% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Beam TherapeuticsOutperform Votes6558.56% Underperform Votes4641.44% Which has higher earnings and valuation, ROIV or BEAM? Roivant Sciences has higher revenue and earnings than Beam Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M58.67$4.35B-$0.15-67.20Beam Therapeutics$63.52M29.03-$132.53M-$4.58-4.03 Which has more volatility & risk, ROIV or BEAM? Roivant Sciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Does the media favor ROIV or BEAM? In the previous week, Beam Therapeutics had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 17 mentions for Beam Therapeutics and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.13 beat Beam Therapeutics' score of 0.20 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend ROIV or BEAM? Roivant Sciences currently has a consensus target price of $17.50, suggesting a potential upside of 73.61%. Beam Therapeutics has a consensus target price of $49.45, suggesting a potential upside of 167.61%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in ROIV or BEAM? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 4.2% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ROIV or BEAM more profitable? Beam Therapeutics has a net margin of -41.07% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Beam Therapeutics -41.07%-16.22%-10.94% SummaryBeam Therapeutics beats Roivant Sciences on 10 of the 18 factors compared between the two stocks. Remove Ads Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.84B$2.98B$5.58B$7.92BDividend YieldN/A1.55%5.35%4.04%P/E Ratio-10.5030.8023.1218.81Price / Sales29.03405.80369.1988.69Price / CashN/A168.6838.1634.64Price / Book1.533.696.704.18Net Income-$132.53M-$72.06M$3.20B$247.10M7 Day Performance-15.65%-6.68%-4.00%-2.96%1 Month Performance-29.84%-16.80%-0.64%-6.48%1 Year Performance-39.51%-28.80%9.09%0.20% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics3.234 of 5 stars$18.48+4.8%$49.45+167.6%-39.5%$1.84B$63.52M-10.50510Short Interest ↑Gap DownROIVRoivant Sciences2.4231 of 5 stars$10.09-2.8%$17.10+69.5%-7.7%$7.20B$122.59M-67.25860LNTHLantheus4.3999 of 5 stars$97.63+1.5%$129.43+32.6%+65.5%$6.69B$1.53B16.24700Positive NewsBBIOBridgeBio Pharma4.6629 of 5 stars$34.59-1.5%$52.64+52.2%+20.2%$6.58B$221.90M-12.14400Analyst ForecastOptions VolumeRVMDRevolution Medicines4.2054 of 5 stars$35.39-5.3%$66.31+87.4%+11.9%$6.58B$742,000.00-9.86250Analyst ForecastNews CoveragePositive NewsLEGNLegend Biotech2.6961 of 5 stars$33.97-3.1%$79.00+132.6%-41.1%$6.24B$627.24M-35.751,070Short Interest ↓Positive NewsTGTXTG Therapeutics3.0584 of 5 stars$39.46-1.0%$40.67+3.1%+175.8%$6.20B$329.00M-394.53290News CoveragePositive NewsSRPTSarepta Therapeutics4.8474 of 5 stars$63.81-9.4%$164.05+157.1%-50.8%$6.19B$1.90B51.051,314Quiet Period ExpirationNews CoverageHigh Trading VolumeAXSMAxsome Therapeutics4.7484 of 5 stars$116.59-1.6%$167.64+43.8%+47.2%$5.69B$385.69M-19.46380Analyst ForecastShort Interest ↓News CoverageBPMCBlueprint Medicines2.8259 of 5 stars$88.60-0.1%$124.95+41.0%-1.7%$5.66B$508.82M-82.03640News CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.76-2.8%$22.00+31.3%N/A$5.65B$783.21M0.00N/AGap Up Remove Ads Related Companies and Tools Related Companies ROIV Alternatives LNTH Alternatives BBIO Alternatives RVMD Alternatives LEGN Alternatives TGTX Alternatives SRPT Alternatives AXSM Alternatives BPMC Alternatives TLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAM) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
